Three-drug combo eliminates pancreatic tumors in mice, signaling potential human therapies
A triple-drug regimen that targets three cancer-growth pathways—KRAS, its related pathway, and STAT3—completely eradicated pancreatic tumors across three mouse models, prevented tumor recurrence for about seven months, and showed no significant toxicity in mice. The treatment uses afatinib, daraxonrasib, and a novel STAT3 inhibitor. While the results are promising, researchers caution that mouse findings may not translate to humans and plan further drug development and clinical testing across diverse KRAS mutations.
